Evidence map›Paper›PMID 35444937›Full record

ArticleFrontiers in oncology2022

BRAF Inhibitor Resistance Confers Increased Sensitivity to Mitotic Inhibitors.

Sean A Misek, Bardees M Foda, Thomas S Dexheimer, Maisah Akram, Susan E Conrad, Jens C Schmidt, Richard R Neubig, Kathleen A Gallo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Sean A MisekDepartment of Physiology, Michigan State University, East Lansing, MI, United States.
Bardees M FodaDepartment of Pharmacology and Toxicology, Michigan State University, East Lansing, MI, United States.
Thomas S DexheimerDepartment of Pharmacology and Toxicology, Michigan State University, East Lansing, MI, United States.
Maisah AkramDepartment of Pharmacology and Toxicology, Michigan State University, East Lansing, MI, United States.
Susan E ConradDepartment of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI, United States.
Jens C SchmidtDepartment of Obstetrics, Gynecology and Reproductive Biology, Michigan State University, East Lansing, MI, United States.
Richard R NeubigDepartment of Pharmacology and Toxicology, Michigan State University, East Lansing, MI, United States.
Kathleen A GalloDepartment of Physiology, Michigan State University, East Lansing, MI, United States.
Michigan State University · US

Funding

Targeting Sox10-low cells in drug-resistant melanomaF31CA232555 · NCI · MICHIGAN STATE UNIVERSITY · PI MISEK, SEAN ALEXANDER · 2018 to 2019
$84k
NCI NIH HHS F31 CA232555
6 · The paper itself

Abstract

Single agent and combination therapy with BRAF

Indexed as

BRAFcompound screeninhibitormelanomamitosispharmacologyresistancevemurafenib

Identifiers

PMID35444937
PMCPMC9015667
OpenAlexW4226142222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.